Business1 min read

Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 crore

By · Published by Everything Blog

In short

Total expenses climbed sharply to ₹6,806.6 crore from ₹4,509 crore in the prior-year period, triggering a notable contraction in quarterly earnings. Conversely, revenue from operations advanced 29.2% to reach ₹7,909.6 crore, supported primarily by the core pharmaceuticals division. Geographically, the India formulations business expanded by 18% to generate ₹1,884.4 crore in revenue. The North America formulations segment also provided substantial support by delivering ₹3,314.5 crore during the three-month span.

Key points

  • The pharmaceuticals business continues to anchor company performance by generating 83% of…: The pharmaceuticals business continues to anchor company performance by generating 83% of aggregate sales.
  • Strong domestic traction was evident as India formulations revenue achieved an 18% increa…: Strong domestic traction was evident as India formulations revenue achieved an 18% increase to ₹1,884.4 crore.
  • North American formulation operations generated ₹3,314.5 crore to reinforce the company's…: North American formulation operations generated ₹3,314.5 crore to reinforce the company's international commercial presence.

Sources checked by our analysis pipeline: 1

The company had posted a net profit of ₹1,260.9 crore in the corresponding period of the previous fiscal year, it said in a regulatory filing.

Read more: Dabur India Q2 Results: Profit rises 12% YoY to Rs 506 crore, revenue up 12%; co declares interim dividend of Rs 3.50/share

Revenue from operations rose 29.2% to ₹7,909.6 crore during the quarter from ₹6,123.2 crore a year earlier. Total expenses increased sharply to ₹6,806.6 crore during the quarter from ₹4,509 crore in the same period last year.

Read more: Lenskart Q2 Results: Profit zooms 122% YoY to Rs 227 crore; revenue grows 36%

During the quarter, the pharmaceuticals business accounted for 83% of the company's sales, Zydus said in a statement.

Its India formulations business reported revenue of ₹1,884.4 crore, up 18% year-on-year, while the North America formulations business posted revenue of ₹3,314.5 crore.

(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies…

Business